Focus IR/London South East CEO interview
We are pleased to share an interview with CEO Dr David Solomon following the proposed acquisition of Sanmirna Therapeutics and £2.75 million fundraise.
If you have any questions, please feel free to submit those below.
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be visible to everyone.
Investor Q&As
Start the conversation
Ask Thalia Therapeutics a question about this update.